Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan - õhukese polümeerikattega tablett - 100mg 90tk; 100mg 30tk; 100mg 100tk; 100mg 28tk; 100mg 56tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan - õhukese polümeerikattega tablett - 25mg 98tk; 25mg 21tk; 25mg 100tk; 25mg 30tk; 25mg 28tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan - õhukese polümeerikattega tablett - 12,5mg 100tk; 12,5mg 98tk; 12,5mg 30tk; 12,5mg 28tk; 12,5mg 21tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+25mg 98tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+12,5mg 98tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 50mg+12,5mg 56tk; 50mg+12,5mg 30tk

Европска Унија - Естонски - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Европска Унија - Естонски - EMA (European Medicines Agency)

ratiopharm gmbh - memantiinvesinikkloriid - alzheimeri tõbi - psychoanaleptics, - mõõduka kuni raske alzheimeri tõvega patsientide ravi.

Европска Унија - Естонски - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatiid - osteoporoos - kaltsiumi homöostaas - movymia on näidustatud täiskasvanutel. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. postmenopausaalsetel naistel on selgelt ja selgroogsete luumurdude, kuid mitte puusaluumurdude esinemissageduse märkimisväärne vähenemine. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - mirtasapiin - õhukese polümeerikattega tablett - 30mg 1000tk; 30mg 100tk; 30mg 500tk; 30mg 20tk; 30mg 200tk; 30mg 150tk; 30mg 28tk; 30mg 90tk; 30mg 60tk; 30mg 350tk; 30mg 300tk; 30mg 40tk; 30mg 110tk; 30mg 250tk; 30mg 50tk; 30mg 98tk; 30mg 48tk